Ki16198 is the methyl ester of Ki16425. Ki16198, a LPA antagonist, inhibits LPA1- and LPA3-induced inositol phosphate production with the Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6[1].
Lysophosphatidic acid (LPA) is an extracellular signaling lipid involved in regulating cell proliferation, survival, and motility of normal and cancer cells[2].
In vitro: In YAPC-PD cancer cell line, Ki16198 substantially inhibited LPA1- and LPA3-mediated responses with low potency to LPA2 and no activity to LPA4, LPA5 and LPA6. Treatment with Ki16198 (10 μM) effectively inhibited migration and invasion responses to LPA in YAPC-PD cancer cell line. Incubation of Ki16198 (10 μM) inhibited the LPA-induced expression of proMMP-9 protein and mRNA in YAPC-PD cells [1].Administration of Ki16198 (1 μM) inhibited the proliferation of lpa1Δ-1 and lpa1Δ+-1 cells by about 70% [2].
In vivo: In YAPC-PD pancreatic cancer cell-inoculated nude xenograft mouse model, Oral administration of Ki16198 (2 mg/kg) significantly inhibited tumor weight and remarkably attenuated invasion and metastasis to lung, liver, and brain and decreased the total metastatic node weight in the peritoneal cavity and ascites formation by 50% [1].Oral administration of Ki16198 (60 mg/kg) significantly inhibited lactate-induced limb lesions in rats [3].
References:
[1]. Komachi M, Sato K, Tobo M, et al. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo[J]. Cancer science, 2012, 103(6): 1099-1104.
[2]. Shano S, Hatanaka K, Ninose S, et al. A lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation[J]. BiochimicaetBiophysicaActa (BBA)-Molecular Cell Research, 2008, 1783(5): 748-759.
[3]. Kimura T, Mogi C, Sato K, et al. p2y5/LPA6 attenuates LPA1-mediated VE-cadherin translocation and cell–cell dissociation through G12/13 protein–Src–Rap1[J]. Cardiovascular research, 2011: cvr154.